|
**Overview**: **CBC Advanced Profile****Introduction**: The CBC Advanced Profile is a diagnostic tool designed to conduct advanced hematology screening using whole blood samples. Associated with conditions like anemia and leukocytosis, these disorders present with fatigue, infection risk, and severe complications if untreated, particularly in individuals with hematological concerns. Per the 2023 Hematology guidelines, the test employs hematology with automated cell counter technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for routine check-ups in clinical settings. This diagnostic falls under routine check-up and targets individuals with suspected hematological disorders, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: CBC Adv Pfl.**FDA Status**: FDA approved, CLIA certified for hematology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1970s by hematology labs, this test advanced advanced blood diagnostics.**Purpose**: The test screens for 24 parameters including hemoglobin to guide hematological assessment, assess blood cell status, and inform treatment and prevention strategies.**Test Parameters**: 1. Hemoglobin, 2. RBC Count, 3. WBC Count, 4. Platelet Count, 5. Hematocrit, 6. MCV, 7. MCH, 8. MCHC, 9. RDW, 10. Neutrophils, 11. Lymphocytes, 12. Monocytes, 13. Eosinophils, 14. Basophils, 15. ESR, 16. Peripheral Smear, 17. Reticulocyte Count, 18. Absolute Neutrophil Count, 19. Absolute Lymphocyte Count, 20. Absolute Monocyte Count, 21. Absolute Eosinophil Count, 22. Absolute Basophil Count, 23. MPV, 24. Platelet Distribution Width.**Pretest Condition**: No fasting required; patients should report fatigue, infection risk, or recent hematological symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve cell integrity.**Medical History**: Patients should provide details on fatigue, infection risk, prior hematological reactions, or family history of blood disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated hematological disorders including organ damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using automated cell counter and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent transfusions can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible hematological disorders, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in hematology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Bone marrow biopsy or iron studies for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in acute inflammation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Hematology Guidelines 2023, Journal of Blood Medicine 2024, Biochemistry 2025. |
